Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Comment on "Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials".

Standing JF, Anderson BJ, Hennig S, Holford NH, Johnston TN, Knibbe CAJ, Lonsdale DO, Rostami-Hodjegan A.

Clin Pharmacokinet. 2018 Jul 20. doi: 10.1007/s40262-018-0697-7. [Epub ahead of print] No abstract available.

PMID:
30027513
2.

What is the best size predictor for dose in the obese child?

Anderson BJ, Holford NH.

Paediatr Anaesth. 2017 Dec;27(12):1176-1184. doi: 10.1111/pan.13272. Epub 2017 Oct 26. Review.

PMID:
29076211
3.

Allometric size: The scientific theory and extension to normal fat mass.

Holford NHG, Anderson BJ.

Eur J Pharm Sci. 2017 Nov 15;109S:S59-S64. doi: 10.1016/j.ejps.2017.05.056. Epub 2017 May 25. Review. No abstract available.

PMID:
28552478
4.

Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients.

Tsuji Y, Holford NHG, Kasai H, Ogami C, Heo YA, Higashi Y, Mizoguchi A, To H, Yamamoto Y.

Br J Clin Pharmacol. 2017 Aug;83(8):1758-1772. doi: 10.1111/bcp.13262. Epub 2017 Mar 31.

5.

Why standards are useful for predicting doses.

Holford NH, Anderson BJ.

Br J Clin Pharmacol. 2017 Apr;83(4):685-687. doi: 10.1111/bcp.13230. Epub 2017 Feb 2.

6.

Getting the dose right for obese children.

Anderson BJ, Holford NH.

Arch Dis Child. 2017 Jan;102(1):54-55. doi: 10.1136/archdischild-2016-311696. Epub 2016 Sep 21. No abstract available.

PMID:
27655657
7.

Salbutamol has rapid onset pharmacodynamics as a bronchodilator.

Sottas CE, Anderson BJ, Holford NH.

Acta Anaesthesiol Scand. 2016 Oct;60(9):1328-31. doi: 10.1111/aas.12769. Epub 2016 Jul 21. No abstract available.

PMID:
27439596
8.

Rocuronium pharmacokinetics and pharmacodynamics in the adductor pollicis and masseter muscles.

Vega EA, Ibacache ME, Anderson BJ, Holford NH, Nazar CE, Solari S, Allende FA, Cortínez LI.

Acta Anaesthesiol Scand. 2016 Jul;60(6):734-46. doi: 10.1111/aas.12703. Epub 2016 Feb 22.

PMID:
26899676
9.

Comment on Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design.

Standing JF, Anderson BJ, Holford NH, Lutsar I, Metsvaht T.

Clin Pharmacokinet. 2015 Dec;54(12):1287-8. doi: 10.1007/s40262-015-0344-5. No abstract available.

PMID:
26547309
10.

Dexmedetomidine pharmacokinetics in the obese.

Cortínez LI, Anderson BJ, Holford NH, Puga V, de la Fuente N, Auad H, Solari S, Allende FA, Ibacache M.

Eur J Clin Pharmacol. 2015 Dec;71(12):1501-8. doi: 10.1007/s00228-015-1948-2. Epub 2015 Sep 26.

PMID:
26407689
11.

Erratum to: does saturable formation of gemcitabine triphosphate occur in patients?

Tham LS, Wang LZ, Soo RA, Lee HS, Lee SC, Goh BC, Holford NH.

Cancer Chemother Pharmacol. 2015 Mar;75(3):657. doi: 10.1007/s00280-015-2678-y. No abstract available.

PMID:
25589221
12.

Postoperative analgesia using diclofenac and acetaminophen in children.

Hannam JA, Anderson BJ, Mahadevan M, Holford NH.

Paediatr Anaesth. 2014 Sep;24(9):953-61. doi: 10.1111/pan.12422. Epub 2014 May 12.

PMID:
24815417
13.

A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis.

Ribba B, Holford NH, Magni P, Trocóniz I, Gueorguieva I, Girard P, Sarr C, Elishmereni M, Kloft C, Friberg LE.

CPT Pharmacometrics Syst Pharmacol. 2014 May 7;3:e113. doi: 10.1038/psp.2014.12.

14.

Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models: a simulation study in population pharmacokinetics.

Thai HT, Mentré F, Holford NH, Veyrat-Follet C, Comets E.

J Pharmacokinet Pharmacodyn. 2014 Feb;41(1):15-33. doi: 10.1007/s10928-013-9343-z. Epub 2013 Dec 8.

15.

Response to Diaz and de Leon "the mathematics of drug dose individualization should be built with random effects linear models".

Holford NH, Buclin T.

Ther Drug Monit. 2013 Dec;35(6):873-4. doi: 10.1097/FTD.0000000000000019. No abstract available.

PMID:
24263647
16.

Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization.

McCune JS, Bemer MJ, Barrett JS, Scott Baker K, Gamis AS, Holford NH.

Clin Cancer Res. 2014 Feb 1;20(3):754-63. doi: 10.1158/1078-0432.CCR-13-1960. Epub 2013 Nov 11.

17.

Pharmacometrics: opportunity for reducing disease burden in the developing world: the case of Africa.

Pillai G, Davies G, Denti P, Steimer JL, McIlleron H, Zvada S, Chigutsa E, Ngaimisi E, Mirza F, Tadmor B, Holford NH.

CPT Pharmacometrics Syst Pharmacol. 2013 Aug 28;2:e69. doi: 10.1038/psp.2013.45.

18.

Understanding dosing: children are small adults, neonates are immature children.

Anderson BJ, Holford NH.

Arch Dis Child. 2013 Sep;98(9):737-44. doi: 10.1136/archdischild-2013-303720. Epub 2013 Jul 5. Review.

PMID:
23832061
19.

The population pharmacokinetics of allopurinol and oxypurinol in patients with gout.

Wright DF, Stamp LK, Merriman TR, Barclay ML, Duffull SB, Holford NH.

Eur J Clin Pharmacol. 2013 Jul;69(7):1411-21. doi: 10.1007/s00228-013-1478-8. Epub 2013 Mar 10.

PMID:
23475133
20.

A comparison of bootstrap approaches for estimating uncertainty of parameters in linear mixed-effects models.

Thai HT, Mentré F, Holford NH, Veyrat-Follet C, Comets E.

Pharm Stat. 2013 May-Jun;12(3):129-40. doi: 10.1002/pst.1561. Epub 2013 Mar 4.

21.

Authors' response to Marras and Oakes, 'Piecing together the puzzle of progression and mortality in Parkinson's disease'.

Holford NH, Vu TC, Nutt JG.

Br J Clin Pharmacol. 2013 May;75(5):1370-1. doi: 10.1111/j.1365-2125.2012.04465.x. No abstract available.

22.

Safe and effective variability-a criterion for dose individualization.

Holford NH, Buclin T.

Ther Drug Monit. 2012 Oct;34(5):565-8. doi: 10.1097/FTD.0b013e31826aabc3.

PMID:
22960736
23.

Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease.

Vu TC, Nutt JG, Holford NH.

Br J Clin Pharmacol. 2012 Aug;74(2):284-95. doi: 10.1111/j.1365-2125.2012.04208.x.

24.

Progression of motor and nonmotor features of Parkinson's disease and their response to treatment.

Vu TC, Nutt JG, Holford NH.

Br J Clin Pharmacol. 2012 Aug;74(2):267-83. doi: 10.1111/j.1365-2125.2012.04192.x.

25.

Prediction of morphine dose in humans.

Holford NH, Ma SC, Anderson BJ.

Paediatr Anaesth. 2012 Mar;22(3):209-22. doi: 10.1111/j.1460-9592.2011.03782.x. Epub 2011 Dec 28.

PMID:
22212108
26.

The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis.

Gengiah TN, Holford NH, Botha JH, Gray AL, Naidoo K, Abdool Karim SS.

Eur J Clin Pharmacol. 2012 May;68(5):689-95. doi: 10.1007/s00228-011-1166-5. Epub 2011 Nov 23.

27.

The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.

Chigutsa E, Visser ME, Swart EC, Denti P, Pushpakom S, Egan D, Holford NH, Smith PJ, Maartens G, Owen A, McIlleron H.

Antimicrob Agents Chemother. 2011 Sep;55(9):4122-7. doi: 10.1128/AAC.01833-10. Epub 2011 Jun 27.

28.

Interpreting the results of Parkinson's disease clinical trials: time for a change.

Holford NH, Nutt JG.

Mov Disord. 2011 Mar;26(4):569-77. doi: 10.1002/mds.23555. Epub 2011 Mar 2.

PMID:
21370266
29.

Predicting weight using postmenstrual age--neonates to adults.

Sumpter AL, Holford NH.

Paediatr Anaesth. 2011 Mar;21(3):309-15. doi: 10.1111/j.1460-9592.2011.03534.x. Erratum in: Paediatr Anaesth. 2012 Jul;22(7):728.

PMID:
21320235
30.

Tips and traps analyzing pediatric PK data.

Anderson BJ, Holford NH.

Paediatr Anaesth. 2011 Mar;21(3):222-37. doi: 10.1111/j.1460-9592.2011.03536.x. Review.

PMID:
21320233
31.

Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens.

Bulitta JB, Kinzig M, Jakob V, Holzgrabe U, Sörgel F, Holford NH.

Br J Clin Pharmacol. 2010 Nov;70(5):682-93. doi: 10.1111/j.1365-2125.2010.03750.x.

32.

Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model.

Cortínez LI, Anderson BJ, Penna A, Olivares L, Muñoz HR, Holford NH, Struys MM, Sepulveda P.

Br J Anaesth. 2010 Oct;105(4):448-56. doi: 10.1093/bja/aeq195. Epub 2010 Aug 14.

33.

A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity.

Patel K, Choy SS, Hicks KO, Melink TJ, Holford NH, Wilson WR.

Cancer Chemother Pharmacol. 2011 May;67(5):1145-55. doi: 10.1007/s00280-010-1412-z. Epub 2010 Aug 4.

PMID:
20683596
34.

Dexmedetomidine hemodynamics in children after cardiac surgery.

Potts AL, Anderson BJ, Holford NH, Vu TC, Warman GR.

Paediatr Anaesth. 2010 May;20(5):425-33. doi: 10.1111/j.1460-9592.2010.03285.x. Epub 2010 Mar 11.

PMID:
20337956
35.

Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study.

Nutt JG, Chung KA, Holford NH.

Neurology. 2010 Apr 13;74(15):1191-7. doi: 10.1212/WNL.0b013e3181d90050. Epub 2010 Mar 10.

36.

Leaving no stone unturned, or extracting blood from stone?

Anderson BJ, Holford NH.

Paediatr Anaesth. 2010 Jan;20(1):1-6. doi: 10.1111/j.1460-9592.2009.03179.x. Epub 2009 Nov 23. No abstract available.

PMID:
19968809
37.

Mechanistic basis of using body size and maturation to predict clearance in humans.

Anderson BJ, Holford NH.

Drug Metab Pharmacokinet. 2009;24(1):25-36. Review.

38.
39.

Human renal function maturation: a quantitative description using weight and postmenstrual age.

Rhodin MM, Anderson BJ, Peters AM, Coulthard MG, Wilkins B, Cole M, Chatelut E, Grubb A, Veal GJ, Keir MJ, Holford NH.

Pediatr Nephrol. 2009 Jan;24(1):67-76. doi: 10.1007/s00467-008-0997-5. Epub 2008 Oct 10.

PMID:
18846389
40.

Population pharmacokinetic and pharmacodynamic modelling of the effects of nicorandil in the treatment of acute heart failure.

Iida S, Kinoshita H, Holford NH.

Br J Clin Pharmacol. 2008 Sep;66(3):352-65. doi: 10.1111/j.1365-2125.2008.03257.x.

41.

Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial.

Anand KJ, Anderson BJ, Holford NH, Hall RW, Young T, Shephard B, Desai NS, Barton BA; NEOPAIN Trial Investigators Group.

Br J Anaesth. 2008 Nov;101(5):680-9. doi: 10.1093/bja/aen248. Epub 2008 Aug 23.

42.

A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients.

Tham LS, Wang L, Soo RA, Lee SC, Lee HS, Yong WP, Goh BC, Holford NH.

Clin Cancer Res. 2008 Jul 1;14(13):4213-8. doi: 10.1158/1078-0432.CCR-07-4754.

43.

Does saturable formation of gemcitabine triphosphate occur in patients?

Tham LS, Wang LZ, Soo RA, Lee HS, Lee SC, Goh BC, Holford NH.

Cancer Chemother Pharmacol. 2008 Dec;63(1):55-64. doi: 10.1007/s00280-008-0707-9. Epub 2008 Feb 28. Erratum in: Cancer Chemother Pharmacol. 2015 Mar;75(3):657.

PMID:
18305939
44.

Investigating the pharmacodynamics of ketamine in children.

Herd DW, Anderson BJ, Keene NA, Holford NH.

Paediatr Anaesth. 2008 Jan;18(1):36-42.

PMID:
18095964
45.
46.

Mechanism-based concepts of size and maturity in pharmacokinetics.

Anderson BJ, Holford NH.

Annu Rev Pharmacol Toxicol. 2008;48:303-32. Review.

PMID:
17914927
47.

Modeling the norketamine metabolite in children and the implications for analgesia.

Herd DW, Anderson BJ, Holford NH.

Paediatr Anaesth. 2007 Sep;17(9):831-40.

PMID:
17683400
48.

Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation.

Chan PL, Nutt JG, Holford NH.

Pharm Res. 2007 Apr;24(4):791-802. Epub 2007 Feb 17.

PMID:
17308968
49.

Population pharmacokinetics of humanized monoclonal antibody HuCC49deltaCH2 and murine antibody CC49 in colorectal cancer patients.

Fang L, Holford NH, Hinkle G, Cao X, Xiao JJ, Bloomston M, Gibbs S, Saif OH, Dalton JT, Chan KK, Schlom J, Martin EW Jr, Sun D.

J Clin Pharmacol. 2007 Feb;47(2):227-37.

PMID:
17244774
50.

Simulation of correlated continuous and categorical variables using a single multivariate distribution.

Tannenbaum SJ, Holford NH, Lee H, Peck CC, Mould DR.

J Pharmacokinet Pharmacodyn. 2006 Dec;33(6):773-94. Epub 2006 Oct 12.

PMID:
17053984

Supplemental Content

Loading ...
Support Center